Detalhe da pesquisa
1.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35179323
2.
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
Cancer
; 130(11): 1930-1939, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38340349
3.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Oncologist
; 29(3): 235-243, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37812679
4.
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Lancet Oncol
; 24(7): 783-797, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414011
5.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
; 399(10336): 1695-1707, 2022 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405085
6.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
N Engl J Med
; 382(23): 2187-2196, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469183
7.
Whole-body MRI in oncology: can a single anatomic T2 Dixon sequence replace the combination of T1 and STIR sequences to detect skeletal metastasis and myeloma?
Eur Radiol
; 33(1): 244-257, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35925384
8.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
N Engl J Med
; 381(26): 2506-2518, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31566937
9.
Whole-body magnetic resonance imaging for prostate cancer assessment: Current status and future directions.
J Magn Reson Imaging
; 55(3): 653-680, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33382151
10.
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.
BJU Int
; 130(1): 68-75, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34706141
11.
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
Future Oncol
; 18(21): 2585-2597, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35656777
12.
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Future Oncol
; 18(35): 3867-3874, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226865
13.
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
Future Oncol
; 18(1): 35-45, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636627
14.
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
Jpn J Clin Oncol
; 51(8): 1287-1297, 2021 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33738495
15.
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Lancet Oncol
; 21(1): e18-e28, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31908301
16.
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Lancet Oncol
; 21(11): 1513-1525, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926841
17.
Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer.
Eur Radiol
; 30(6): 3083-3093, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32065282
18.
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 20(4): 556-569, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770294
19.
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(3): 408-419, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30738780
20.
Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
BJU Int
; 123(3): 411-420, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30240059